The Illumina analysis showed a higher somatic mutation frequency for TP53, NOTCH1/2, MYH9, BRCA1/2, ERBB4, POLE, FGFR3, ROS1, NOTCH4, LAMA2, EGFR, ESR1, THBS1, and CASp8, and a lower somatic mutation frequency for CDH1 in the IBC patients in comparison to the non-IBC ones. This evidence concerns the gene POLE and inflammatory breast carcinoma.